Crucell, DSM Biologics N.V. deal

CRXL and DSM expanded a 2002 deal under which the companies jointly license CRXL's PER.C6 cell line to third parties to produce MAbs and therapeutic proteins (see BioCentury, Dec. 23, 2002). The deal ...